Hidetaka Koizumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hidetaka Koizumi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ryuji Kaji
Tokushima University Graduate School of Medicine, Tokushima, Japan
3 shared publications - Yuishin Izumi
Department of Neurology, Tokushima University, Tokushima, Japan; Department of Neurology, Vihara Hananosato Hospital, Hiroshima, Japan
2 shared publications - Etsuro Ohta
Division of Blood Transfusion and Transplantation, Kitasato University School of Health Sciences, Minamiuonuma 949-7241, Nigata, Japan
1 shared publication - Fumiya Obata
Division of Immunology, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan
1 shared publication - Masanori Nakagawa
North Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan
1 shared publication - Masatoshi Takahashi
Department of Neurology, Shinko Hospital Kobe, Japan
1 shared publication
Latest Publications
- Open Access
- 6 June 2016
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 10, 226
Edrophonium Challenge Test for Blepharospasm
Background: Blepharospasm is typically diagnosed clinically by excluding any secondary diseases and neuropsychiatric disorders because specific tests for blepharospasm are currently unavailable. Since anticholinergic agents are used to improve the symptoms of dystonia, we hypothesized that edrophonium chloride, an acetylcholinesterase inhibitor, may make the symptoms of dystonia apparent. Therefore, we examined whether an edrophonium challenge test would be useful in the diagnosis of blepharospasm. Methods: We studied 10 patients with blepharospasm and 10 with hemifacial spasms (as disease controls). We administered edrophonium and saline in this crossover study. Before and after the injection, we recorded the clinical signs using a video camera to assess the objective symptoms every 2 min. Ten minutes after the isotonic sodium chloride and edrophonium injections, the patients evaluated their subjective signs using a visual analog scale. The objective signs on the video recordings were scored by specialists who were blind to the treatment. Results: The subjective and objective signs of the patients with blepharospasm were amplified by edrophonium. In contrast, in patients with hemifacial spasms, the signs were not changed by the edrophonium challenge test. Conclusions: The edrophonium challenge test may be used to diagnose blepharospasm.
- 6 June 2016
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 10, 226
Open AccessEdrophonium Challenge Test for Blepharospasm
Background: Blepharospasm is typically diagnosed clinically by excluding any secondary diseases and neuropsychiatric disorders because specific tests for blepharospasm are currently unavailable. Since anticholinergic agents are used to improve the symptoms of dystonia, we hypothesized that edrophonium chloride, an acetylcholinesterase inhibitor, may make the symptoms of dystonia apparent. Therefore, we examined whether an edrophonium challenge test would be useful in the diagnosis of blepharospasm. Methods: We studied 10 patients with blepharospasm and 10 with hemifacial spasms (as disease controls). We administered edrophonium and saline in this crossover study. Before and after the injection, we recorded the clinical signs using a video camera to assess the objective symptoms every 2 min. Ten minutes after the isotonic sodium chloride and edrophonium injections, the patients evaluated their subjective signs using a visual analog scale. The objective signs on the video recordings were scored by specialists who were blind to the treatment. Results: The subjective and objective signs of the patients with blepharospasm were amplified by edrophonium. In contrast, in patients with hemifacial spasms, the signs were not changed by the edrophonium challenge test. Conclusions: The edrophonium challenge test may be used to diagnose blepharospasm.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 7, 74
Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role
The opioid peptide receptors consist of three major subclasses, namely, μ, δ, and κ (MOR, DOR, and KOR, respectively). They are involved in the regulation of striatal dopamine functions, and increased opioid transmissions are thought to play a compensatory role in altered functions of the basal ganglia in Parkinson's disease (PD). In this study, we used an immunohistochemistry with tyramide signal amplification (TSA) protocols to determine the distributional patterns of opioid receptors in the striosome-matrix systems of the rat striatum. As a most striking feature of striatal opioid anatomy, MORs are highly enriched in the striosomes and subcallosal streak. We also found that DORs are localized in a mosaic pattern in the dorsal striatum (caudate-putamen), with heightened labeling for DOR in the striosomes relative to the matrix compartment. In the 6-hydroxydopamine-lesioned rat model of PD, lesions of the nigrostriatal pathways caused a significant reduction of striatal labeling for both the MOR and DOR in the striosomes, but not in the matrix compartment. Our results suggest that the activities of the striosome and matrix compartments are differentially regulated by the opioid signals involving the MORs and DORs, and that the striosomes may be more responsive to opioid peptides (e.g., enkephalin) than the matrix compartment. Based on a model in which the striosome compartment regulates the striatal activity, we propose a potent compensatory role of striosomal opioid signaling under the conditions of the striatal dopamine depletion that occurs in PD.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 7, 74
Open AccessResponse of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role
The opioid peptide receptors consist of three major subclasses, namely, μ, δ, and κ (MOR, DOR, and KOR, respectively). They are involved in the regulation of striatal dopamine functions, and increased opioid transmissions are thought to play a compensatory role in altered functions of the basal ganglia in Parkinson's disease (PD). In this study, we used an immunohistochemistry with tyramide signal amplification (TSA) protocols to determine the distributional patterns of opioid receptors in the striosome-matrix systems of the rat striatum. As a most striking feature of striatal opioid anatomy, MORs are highly enriched in the striosomes and subcallosal streak. We also found that DORs are localized in a mosaic pattern in the dorsal striatum (caudate-putamen), with heightened labeling for DOR in the striosomes relative to the matrix compartment. In the 6-hydroxydopamine-lesioned rat model of PD, lesions of the nigrostriatal pathways caused a significant reduction of striatal labeling for both the MOR and DOR in the striosomes, but not in the matrix compartment. Our results suggest that the activities of the striosome and matrix compartments are differentially regulated by the opioid signals involving the MORs and DORs, and that the striosomes may be more responsive to opioid peptides (e.g., enkephalin) than the matrix compartment. Based on a model in which the striosome compartment regulates the striatal activity, we propose a potent compensatory role of striosomal opioid signaling under the conditions of the striatal dopamine depletion that occurs in PD.
- 20 July 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (10) , 1324-1325
Broad spectrum of dystonia associated with a novel thanatosis-associated protein domain-containing apoptosis-associated protein 1 mutation in a Japanese family with dystonia 6, torsion
- 20 July 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (10) , 1324-1325
Broad spectrum of dystonia associated with a novel thanatosis-associated protein domain-containing apoptosis-associated protein 1 mutation in a Japanese family with dystonia 6, torsion